News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily｜Iran Conflict Boosts Oil Prices;U.S. Plans Global AI Chip Controls;Non-Farm Data Imminent (2026-03-06)2Broadcom FY2026 Q1 Earnings: AI Revenue Doubles, Record Results, Strong Guidance, $10B Buyback3If the Strait of Hormuz is closed for another 3 days, 3.3 million barrels of crude oil in the Middle East will be forced to halt production, with Iraq being the hardest hit!
USD/CNH: Upside risks as strong fix meets USD demand – OCBC
101 finance·2026/03/06 21:54
Are you a young male who supported Trump and are now struggling to secure employment?
101 finance·2026/03/06 21:45
Trump Announces Defense Companies Will Increase Production of Certain Weapons Fourfold
101 finance·2026/03/06 21:39
Airlines Face Bear Market as Oil Prices Present a ‘Critical’ Challenge
101 finance·2026/03/06 21:39
Plan surfaces for $166 billion in tariff reimbursements. However, don't expect it to happen soon.
101 finance·2026/03/06 21:39
Florida Gov. Ron DeSantis Eyes State Stablecoin Framework Following Senate Passage
101 finance·2026/03/06 21:36
Robinhood CEO states that every newborn will have access to a Trump account
101 finance·2026/03/06 21:18
Here’s what could happen to container shipping rates if the Iran conflict continues
101 finance·2026/03/06 21:15
Broadcom’s AI Order Backlog Hides a High-Conviction Growth Setup for Patient Capital
101 finance·2026/03/06 21:13
Flash
22:00
Sylvamo has filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that selling shareholders plan a secondary offering of common stock, with the issuance scale up to 6.3 million shares.This offering will be solely managed by the selling shareholders, and Sylvamo will not receive any proceeds from the sale of these shares.
21:59
Incyte recently announced that its innovative drug Zynyz® (Retifanlimab) has been approved by the European Commission as a first-line treatment for advanced squamous cell anal carcinoma (SCAC).This approval marks the official entry of this immunotherapy into the European market, providing patients with a new treatment option.
21:52
Spot gold fell 2% this week, silver dropped 10% cumulatively, and platinum fell more than 9% cumulatively.COMEX gold futures rose by 1.90%, quoted at $5,175.00 per ounce, with a cumulative decline of 1.30% this week. Spot silver increased by 2.55%, quoted at $84.3451 per ounce, with a cumulative decline of 10.06% this week. COMEX silver futures rose by 2.88%, quoted at $84.545 per ounce, with a cumulative decline of 9.35% this week. COMEX copper futures increased by 0.59%, quoted at $5.8385 per pound, with a cumulative decline of 3.64% this week. Spot platinum rose by 0.98%, with a cumulative decline of 9.51% this week; spot palladium fell by 0.58%, with a cumulative decline of 8.97% this week.
Trending news
MoreSylvamo has filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that selling shareholders plan a secondary offering of common stock, with the issuance scale up to 6.3 million shares.
Incyte recently announced that its innovative drug Zynyz® (Retifanlimab) has been approved by the European Commission as a first-line treatment for advanced squamous cell anal carcinoma (SCAC).
News